FDA Puts Stronger Warnings on Anti-Depressants

The FDA will expand its black box warning on certain anti-depressant drugs due to heightened suicidal risks for those up to age 24. The new warning is different from the previous one because it specifies an age limit. According to an article published in the Wall St. Journal, “Before that panel meeting, the FDA first proposed updating the black-box warnings on antidepressants after reviewing data from 372 clinical studies involving 11 antidepressants, including GlaxoSmithKline PLC’s Paxil, Pfizer Inc.’s Zoloft and Eli Lilly & Co.’s Prozac. More than 77,000 patients were involved in the studies.” According to the FDA, the review found a greater risk of suicidality among those taking anti-depressants in the 18-24 age category.